79,683 Shares in ANI Pharmaceuticals, Inc. $ANIP Purchased by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 79,683 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,597,000. Jupiter Topco LLC owned approximately 0.35% of ANI Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC purchased a new position in ANI Pharmaceuticals in the first quarter valued at about $2,706,000. Finally, Norges Bank purchased a new position in ANI Pharmaceuticals in the second quarter valued at about $625,000. Institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Canaccord Genuity Group lowered their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Guggenheim reduced their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.83.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $72.83 on Monday. The company has a fifty day simple moving average of $79.68 and a two-hundred day simple moving average of $78.64. The stock has a market cap of $1.67 billion, a P/E ratio of 15.70 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total value of $401,220.00. Following the sale, the chief executive officer owned 344,489 shares in the company, valued at $25,595,532.70. This represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the sale, the vice president owned 74,424 shares of the company’s stock, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 24,387 shares of company stock valued at $1,947,625. 8.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.